Long-term treatment of rheumatoid arthritis with tumour necrosis factor blockade: outcome of ceasing and restarting biologicals
Open Access
- 16 September 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 43 (2) , 243-244
- https://doi.org/10.1093/rheumatology/keg454
Abstract
Sir, Infliximab, a chimeric monoclonal antibody, has demonstrated effective suppression of disease and prevention of the progression of structural damage in rheumatoid arthritis (RA) in its phase III randomized study (ATTRACT study) [1, 2]. Two anti-tumour-necrosis factor α (TNF-α) drugs, infliximab and etanercept, have recently been approved by the National Institute of Clinical Excellence [3].Keywords
This publication has 0 references indexed in Scilit: